Core A combines the solid support of MIRT administration with the innovation of Cancer Research and Biostatistics (CRAB) and the superb attention to detail of our data management team to ensure the efforts of all P01 projects and cores are both tangible and accessible. The structure of this P01 has afforded discoveries that were critically dependent on a large patient referral base with fight, long-term follow-up; integrated basic-clinical investigation; and statistical power to interpret findings in the context of historical patients with comprehensive annotations of clinical course and therapeutic interventions as well as availability of samples and laboratory correlates in our multiple myeloma (MM) database (MMDB) system. We have generated an unprecedented treasure of serially obtained bone marrow samples annotated according to the phase of therapy at the time of procurement as well as serial MRI and PET-CT studies for virtually all patients. This wealth of data requires a solid administrative and data management infrastructure to maintain its validity and utility. Core A provides this through Administration, Biostatistics, and Research Coordination components that have been designed to support 4 projects and 4 additional cores.
Aim 1 will provide administrative support to enable the entire Program Project to function as an integrated whole. Over the previous 15 years of funding, this program has supported, on average, 30 PIs and Co-Is and more than 60 Research Associates/Assistants, Post-doctoral Fellows, and other research personnel. The Administration Component will continue to ensure that support is provided to all projects and cores, so research activities are coordinated and have appropriate interactions to accomplish the goals of this Program Project.
Aim 2 will apply biostatistical principles and data management methods to Program Project studies in an effort to ensure in-depth and timely attention to all aspects of data collection as well as execution of increasingly sophisticated biostatistical analyses and bioinformatics. The Biostatistics component, through the innovative efforts of CRAB, will continue to enable researchers of this program to link study design, data collection, measurement, and analysis to the research hypotheses and research questions being investigated.
Aim 3 will provide research coordination that ensures the timely and accurate identification and retrieval of all data associated with MIRT patients in the context of unique patient characteristics, including prognostic features, therapeutic interventions, and serial GEP and imaging data.

Public Health Relevance

The inter-related activities of Core A will not only provide the necessary infrastructure to ensure that day-today operations of the Program Project run smoothly, but will also allow the rapid identification and dissemination of discoveries by individual projects to the other projects and, where appropriate, assess whether a need exists for adjusting research objectives and treatment approaches pursued in this program. As in the past, our successes will be promptly shared with the research community at large.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA055819-18
Application #
8555172
Study Section
Special Emphasis Panel (ZCA1-RPRB-J (M1))
Project Start
2000-06-05
Project End
2014-08-31
Budget Start
2012-09-11
Budget End
2013-08-31
Support Year
18
Fiscal Year
2012
Total Cost
$909,573
Indirect Cost
$281,964
Name
University of Arkansas for Medical Sciences
Department
Type
DUNS #
122452563
City
Little Rock
State
AR
Country
United States
Zip Code
72205
Mikulasova, Aneta; Wardell, Christopher P; Murison, Alexander et al. (2017) The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma. Haematologica 102:1617-1625
Rasche, Leo; Weinhold, Niels; Morgan, Gareth J et al. (2017) Immunologic approaches for the treatment of multiple myeloma. Cancer Treat Rev 55:190-199
Rasche, L; Chavan, S S; Stephens, O W et al. (2017) Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nat Commun 8:268
Went, M; Sud, A; Law, P J et al. (2017) Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach. Blood Cancer J 7:e573
Schinke, Carolina; Hoering, Antje; Wang, Hongwei et al. (2017) The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype. Haematologica 102:e313-e316
Chavan, S S; He, J; Tytarenko, R et al. (2017) Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker. Blood Cancer J 7:e535
Sawyer, J R; Tian, E; Shaughnessy Jr, J D et al. (2017) Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma. Leukemia 31:637-644
Mohan, Meera; Samant, Rohan S; Yoon, Donghoon et al. (2017) Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple Myeloma. J Bone Miner Res 32:1261-1266
Rasche, Leo; Angtuaco, Edgardo; McDonald, James E et al. (2017) Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. Blood 130:30-34
Stein, Caleb K; Pawlyn, Charlotte; Chavan, Shweta et al. (2017) The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma. Oncotarget 8:27854-27867

Showing the most recent 10 out of 284 publications